GlassScriptPhysician profile
Heather B Nelson
NPI 1013001775
$1,783.46
in general payments reported to CMS, 2019-2025
26 companies · $328 in 2025
The $328 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $481 · 2023: $67.52 · 2024: $907 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,302.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $325.89 | 2021-2025 | Airsupra, Farxiga |
| Pfizer INC. | $252.32 | 2021-2025 | |
| Abbvie INC. | $140.67 | 2021-2025 | |
| Novo Nordisk INC | $105.75 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $98.82 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $96.34 | 2021-2024 | Mounjaro |
| Dexcom, INC. | $88.49 | 2021-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $77.86 | 2021-2025 | Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $75.19 | 2024 | |
| Novartis Pharmaceuticals Corporation | $73.71 | 2021-2025 | |
| Esperion Therapeutics, INC. | $56.54 | 2021 | |
| Glaxosmithkline, LLC. | $55.33 | 2021-2025 | Trelegy Ellipta |
| Eisai INC. | $53.26 | 2024 | |
| Astellas Pharma US INC | $44.34 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $41.32 | 2024-2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $23.24 | 2024 | Voquezna |
| Abbott Laboratories | $22.22 | 2024 | Freestyle Libre 3 |
| Shield Therapeutics INC | $19.83 | 2025 | |
| Boston Scientific Corporation | $19.64 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.49 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.47 | 2023 | |
| Tolmar, INC. | $17.10 | 2024 | |
| Amgen INC. | $16.40 | 2021 | |
| Currax Pharmaceuticals LLC | $14.75 | 2021 | |
| Nevro Corp. | $13.77 | 2024 | Senza |
| Kowa Pharmaceuticals America, INC. | $13.72 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.